Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.

BACKGROUND AND OBJECTIVES Flow cytometry enumeration of peripheral blood CD34-positive cells provides reliable measurements of circulating hematopoietic progenitors in humans. Since the absolute number of circulating CD34-positive cells has been previously found to be elevated in myelofibrosis with myeloid metaplasia (MMM), we prospectively studied the clinical utility of this parameter in the work-up of patients with chronic myeloproliferative disorders. DESIGN AND METHODS Of the 248 consecutive patients enrolled in this study, 106 had polycythemia vera (PV), 90 essential thrombocythemia (ET), and 52 myelofibrosis with myeloid metaplasia (MMM). The study population included both newly diagnosed and established cases, and of these latter some patients were on cytoreductive treatment while others were chemotherapy naive. Both cross-sectional and longitudinal investigations were carried out. Flow cytometry enumeration of CD34-positive cells was performed using a single-platform assay. RESULTS Median numbers and ranges of circulating CD34-positive cells were 2.3x10(6)/L (0-5) in 20 control subjects, 2.2x10(6)/L (0-14) in those with PV, 2.4x10(6)/L (0-14) in those with ET, and 114x10(6)/L (6-2,520) in MMM patients. Analysis of variance demonstrated that values were markedly higher in MMM patients than in the remaining groups, and counts did not appear to fluctuate over short periods of follow-up. In both cross-sectional and longitudinal investigations on patients at clinical onset and/or out of cytoreductive treatment, a CD34-positive count of > or = 15x10(6)/L was always associated with MMM, clearly indicating a disease-related specificity. INTERPRETATION AND CONCLUSIONS The absolute number of circulating CD34-positive cells is normal or anyhow lower than 15x10(6)/L in patients with uncomplicated PV or ET, whereas it is equal or above this cut-off in those with MMM, likely reflecting abnormal hematopoietic progenitor cell trafficking. Thus, enumeration of circulating CD34-positive cells may be useful in the work-up of patients with myeloproliferative disorders.

[1]  R. Kralovics,et al.  Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. , 2003, Blood.

[2]  J. Abkowitz,et al.  Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. , 2003, Blood.

[3]  J. Jelinek,et al.  Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. , 2003, Blood.

[4]  C. Pascutto,et al.  Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. , 2003, Haematologica.

[5]  J. Spivak,et al.  Polycythemia vera: myths, mechanisms, and management. , 2002, Blood.

[6]  L. Larocca,et al.  Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  B. Swolin,et al.  Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia , 2002, European journal of haematology.

[8]  M. Cazzola,et al.  Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis , 2002, British journal of haematology.

[9]  V. Deneys,et al.  Clinical value of the quantitative expression of the three epitopes of CD34 in 300 cases of acute myeloid leukemia. , 2002, Haematologica.

[10]  G. Barosi,et al.  Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. , 2001, Blood.

[11]  D Barnett,et al.  Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. European Working Group on Clinical Cell Analysis. , 2000, Cytometry.

[12]  A. Tefferi.  Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.

[13]  B. Swolin,et al.  Hydroxyurea treatment reduces haematopoietic progenitor growth and CD34 positive cells in polycythaemia vera and essential thrombocythaemia , 2000, European journal of haematology.

[14]  M. Tomonaga,et al.  Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry. , 2000, Leukemia research.

[15]  M. Lübbert,et al.  Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. , 2000, Blood.

[16]  A. Green,et al.  A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment. , 2000, Hematology. American Society of Hematology. Education Program.

[17]  G. Barosi.  Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  G. Barosi,et al.  The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia , 1999, British journal of haematology.

[19]  D. Sutherland,et al.  Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. , 1998, Cytometry.

[20]  M. Cazzola,et al.  Both cycling and noncycling primitive progenitors continue to be mobilized into the circulation during the leukapheresis of patients pretreated with chemotherapy and G‐CSF , 1997, British journal of haematology.

[21]  B. Swolin,et al.  Increase of CD34 positive cells in polycythaemia vera , 1997, European journal of haematology.

[22]  J. Laszlo,et al.  Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. , 1997, Seminars in hematology.

[23]  M. Fackler,et al.  CD34: structure, biology, and clinical utility. , 1996, Blood.

[24]  G. Barosi,et al.  Chronic myelofibrosis with myeloid metaplasia. The spectrum of clinical syndromes. , 1987, Haematologica.

[25]  J. Laszlo,et al.  Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. , 1986, Seminars in hematology.

[26]  S. Lewis,et al.  Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders , 1984, British journal of haematology.

[27]  D. Douer,et al.  Circulating pluripotent haemopoietic cells in patients with myeloproliferative disorders , 1983, British journal of haematology.

[28]  N. Berlin.  Diagnosis and classification of the polycythemias. , 1975, Seminars in hematology.